Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | The future of CTCL therapy

Julia Jane Scarisbrick • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Brentuximab vedotin Chlormethine Mogamulizumab

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, shares her views on the future of cutaneous T-cell lymphoma (CTCL) therapy, highlighting the unmet need for more efficacious therapies and to determine the optimal sequencing of therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Julia Jane Scarisbrick

0:59
PROCLIPI: identification of key prognostic factors in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:59
MAVORIC: mogamulizumab improves PFS for CTCL
Julia Jane Scarisbrick • 15 Oct 2021
0:46
ALCANZA: brentuximab vedotin improves ORR and PFS in CTCL
Julia Jane Scarisbrick • 15 Oct 2021
1:10
The role of transplant in CTCL
Julia Jane Scarisbrick • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals